Case Insight: Piramal Pharma’s acquisition of Hemmo Pharmaceuticals

Piramal Pharma Ltd has completed the acquisition of Hemmo Pharmaceuticals. In March this year, Piramal Pharma Ltd entered into an agreement to acquire a 100 per cent stake in Hemmo Pharmaceuticals for an upfront consideration of Rs 775 crore and earn-outs linked to the achievement of milestones. With the addition of Hemmo’s capabilities, Piramal Pharma will gain access to the growing peptide Active Pharmaceutical Ingredient (API) market and enhance its ability to offer integrated services to its customers globally, Piramal Pharma had said in a statement in March.